The Specific Antiviral Drugs for COVID-19 segmentation by application distinguishes three primary usage contexts: Hospitalized treatment, Outpatient treatment, and Prophylaxis. Hospitalized treatment accounts for the largest share of revenue because severe cases require higher‑dose regimens, intravenous formulations, and extended therapy durations, driving both unit price and volume. Outpatient treatment captures a growing middle tier as oral antivirals gain regulatory approval for early‑stage disease, offering a lower price point but higher prescription frequency. Prophylaxis—administered to high‑risk populations for infection prevention—contributes a smaller but strategically important portion of the market, reflecting limited uptake due to cost constraints and targeted eligibility criteria. Together, these application segments shape the overall market size by aligning product pricing, dosage intensity, and distribution channels with clinical need, thereby informing investment decisions and pipeline prioritization.